Highlights Cannara Biotech Inc.

Equities

LOVE

CA13765U2002

Delayed Toronto S.E. Other stock markets 01:11:03 30/05/2024 am IST			5-day change	1st Jan Change
0.74 ^CAD	+1.37%		-7.50%	-10.84%

29/04	Cannara Biotech Turns Negative As Reports Wider Q2 Net Loss Vs a Year Ago, Despite Revenue up 51%	MT
29/04	Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cannara Biotech Turns Negative As Reports Wider Q2 Net Loss Vs a Year Ago, Despite Revenue up 51%	30/04	MT
Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	30/04	CI
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	30/01	CI
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	07/12	CI
Cannara Biotech's Fiscal Q4 Profit, Revenue Grows; Up 9.4%	07/12	MT
Cannara Biotech Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	07/12	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	27/23/27	CI
Cannara Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	27/23/27	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	24/23/24	CI
Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	24/23/24	CI
Cannara Biotech Down Near 8% As Enters into an Automatic Share Purchase Plan	01/23/01	MT
Cannara Biotech Converts CA$5 Million Debenture, Plus Interest, into Nearly 30 Million Shares for Olymbec Investments	10/23/10	MT
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	23/23/23	CI
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	23/23/23	CI
Cannara Biotech Reports Normal Course Issuer Bid for Common Shares	30/22/30	MT
Cannara Biotech Inc. announces an Equity Buyback for 15,000,000 shares, representing 1.71% of its issued share capital.	30/22/30	CI
Cannara Biotech Gains 5% as Q4 EPS Unchanged at $0.01 Vs Year Ago; Revenue $11.9 Million Vs $6.5 Million	25/22/25	MT
Cannara Biotech Q4 EPS Unchanged at $0.01 Vs Year Ago; Revenue $11.9 Million Vs $6.5 Million	25/22/25	MT
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2022	25/22/25	CI
Cannara Biotech Inc. authorizes a Buyback Plan.	11/22/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cannara Biotech Inc.

Equities

LOVE

CA13765U2002

Highlights

Filters